Trinity Biotech gets $7.0 million from Perceptive, regains Nasdaq bid price compliance
The Dublin-based diagnostics company disclosed the funding amendment and Nasdaq notice in a 6-K dated August 14, 2026.
Trinity Biotech plc announced on August 14, 2026 that it secured additional investment of approximately $7.0 million of additional investment to further support strategic growth initiatives including CGM+, Trinovium and the Company's business transformation1 from funds managed by Perceptive Advisors, which the company described as a leading life sciences investment firm and Trinity Biotech's largest financial investor and primary lender1.
The funding is structured as approximately $2.5 million of new debt funding and approximately $4.5 million of capitalised interest under an amendment to the Company's existing financing arrangements1. Per the accompanying 6-K explanatory note, this reflects an amendment to the credit agreement governing the companies' term loan facility with Perceptive Credit Holdings III, L.P., entered into on August 12, 2026, providing for a total investment of approximately $7.0 million1.
Separately, Trinity Biotech said it received confirmation from The Nasdaq Stock Market LLC on August 7, 2026 that it had regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5450(a)(1), after its ADSs closed at $1.00 or greater for 10 consecutive business days from July 24 through August 6, 20261.
The company also disclosed preliminary quarterly figures, reporting preliminary revenues for the quarter ended June 30, 2026 of approximately $10.5 million1, a level it said was little changed from the prior quarter as it works through what it called its operational transformation. Trinity Biotech said it is in the later stages of a broader strategic repositioning tied to changes in healthcare markets and technology, and that it continues to explore technology acquisitions and strategic partnerships with companies engaged in the development of human diagnostics and diabetes management solutions, including products that complement Trinity's CGM+'s wearable biosensor product that is under development1.
As of August 13, 2026, the company reported 487,879,340 ordinary shares outstanding excluding Treasury Shares, with each ADS representing 600 ordinary shares1.
Written by readthrough’s AI from the linked primary sources and fact-checked against them automatically before publishing. Not investment advice.